<?xml version='1.0' encoding='utf-8'?>
<document id="26976869"><sentence text="Characterization of 22 Antituberculosis Drugs for Inhibitory Interaction Potential on Organic Anionic Transporter Polypeptide (OATP)-Mediated Uptake." /><sentence text="We investigated the inhibitory interaction potential of 22 currently marketed antituberculosis (TB) drugs on organic anion-transporting polypeptide 1B1 (OATP1B1)-, OATP2B1-, and OATP1B3-mediated uptake using in vitro Xenopus oocytes and HEK cells" /><sentence text=" Rifabutin, ethambutol, amoxicillin, linezolid, p-amino salicylic acid, and rifapentine exhibited mild to moderate inhibitory effects on OATP-mediated uptake of estrone-3 sulfate, estradiol 17β-d-glucuronide, and rosuvastatin"><entity charOffset="1-10" id="DDI-PubMed.26976869.s3.e0" text="Rifabutin" /><entity charOffset="12-22" id="DDI-PubMed.26976869.s3.e1" text="ethambutol" /><entity charOffset="24-35" id="DDI-PubMed.26976869.s3.e2" text="amoxicillin" /><entity charOffset="37-46" id="DDI-PubMed.26976869.s3.e3" text="linezolid" /><entity charOffset="48-70" id="DDI-PubMed.26976869.s3.e4" text="p-amino salicylic acid" /><entity charOffset="76-87" id="DDI-PubMed.26976869.s3.e5" text="rifapentine" /><entity charOffset="161-178" id="DDI-PubMed.26976869.s3.e6" text="estrone-3 sulfate" /><entity charOffset="180-207" id="DDI-PubMed.26976869.s3.e7" text="estradiol 17β-d-glucuronide" /><entity charOffset="213-225" id="DDI-PubMed.26976869.s3.e8" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e0" e2="DDI-PubMed.26976869.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e0" e2="DDI-PubMed.26976869.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e0" e2="DDI-PubMed.26976869.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e0" e2="DDI-PubMed.26976869.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e0" e2="DDI-PubMed.26976869.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e0" e2="DDI-PubMed.26976869.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e0" e2="DDI-PubMed.26976869.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e0" e2="DDI-PubMed.26976869.s3.e7" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e0" e2="DDI-PubMed.26976869.s3.e8" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e1" e2="DDI-PubMed.26976869.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e1" e2="DDI-PubMed.26976869.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e1" e2="DDI-PubMed.26976869.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e1" e2="DDI-PubMed.26976869.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e1" e2="DDI-PubMed.26976869.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e1" e2="DDI-PubMed.26976869.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e1" e2="DDI-PubMed.26976869.s3.e7" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e1" e2="DDI-PubMed.26976869.s3.e8" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e2" e2="DDI-PubMed.26976869.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e2" e2="DDI-PubMed.26976869.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e2" e2="DDI-PubMed.26976869.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e2" e2="DDI-PubMed.26976869.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e2" e2="DDI-PubMed.26976869.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e2" e2="DDI-PubMed.26976869.s3.e7" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e2" e2="DDI-PubMed.26976869.s3.e8" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e3" e2="DDI-PubMed.26976869.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e3" e2="DDI-PubMed.26976869.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e3" e2="DDI-PubMed.26976869.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e3" e2="DDI-PubMed.26976869.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e3" e2="DDI-PubMed.26976869.s3.e7" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e3" e2="DDI-PubMed.26976869.s3.e8" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e4" e2="DDI-PubMed.26976869.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e4" e2="DDI-PubMed.26976869.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e4" e2="DDI-PubMed.26976869.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e4" e2="DDI-PubMed.26976869.s3.e7" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e4" e2="DDI-PubMed.26976869.s3.e8" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e5" e2="DDI-PubMed.26976869.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e5" e2="DDI-PubMed.26976869.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e5" e2="DDI-PubMed.26976869.s3.e7" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e5" e2="DDI-PubMed.26976869.s3.e8" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e6" e2="DDI-PubMed.26976869.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e6" e2="DDI-PubMed.26976869.s3.e7" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e6" e2="DDI-PubMed.26976869.s3.e8" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e7" e2="DDI-PubMed.26976869.s3.e7" /><pair ddi="false" e1="DDI-PubMed.26976869.s3.e7" e2="DDI-PubMed.26976869.s3.e8" /></sentence><sentence text=" The 50% inhibitory concentration (IC50) values of rifabutin, amoxicillin, ethambutol, p-amino salicylic acid, and linezolid were 35"><entity charOffset="51-60" id="DDI-PubMed.26976869.s4.e0" text="rifabutin" /><entity charOffset="62-73" id="DDI-PubMed.26976869.s4.e1" text="amoxicillin" /><entity charOffset="75-85" id="DDI-PubMed.26976869.s4.e2" text="ethambutol" /><entity charOffset="87-109" id="DDI-PubMed.26976869.s4.e3" text="p-amino salicylic acid" /><entity charOffset="115-124" id="DDI-PubMed.26976869.s4.e4" text="linezolid" /><pair ddi="false" e1="DDI-PubMed.26976869.s4.e0" e2="DDI-PubMed.26976869.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26976869.s4.e0" e2="DDI-PubMed.26976869.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26976869.s4.e0" e2="DDI-PubMed.26976869.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26976869.s4.e0" e2="DDI-PubMed.26976869.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26976869.s4.e0" e2="DDI-PubMed.26976869.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26976869.s4.e1" e2="DDI-PubMed.26976869.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26976869.s4.e1" e2="DDI-PubMed.26976869.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26976869.s4.e1" e2="DDI-PubMed.26976869.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26976869.s4.e1" e2="DDI-PubMed.26976869.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26976869.s4.e2" e2="DDI-PubMed.26976869.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26976869.s4.e2" e2="DDI-PubMed.26976869.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26976869.s4.e2" e2="DDI-PubMed.26976869.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26976869.s4.e3" e2="DDI-PubMed.26976869.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26976869.s4.e3" e2="DDI-PubMed.26976869.s4.e4" /></sentence><sentence text="4, 36" /><sentence text="2, 57" /><sentence text="6, 72" /><sentence text="6, and 65" /><sentence text="9 μM, respectively, for uptake mediated by organic anionic transporter polypeptide 1B1 (OATP1B1) and 28" /><sentence text="8, 28" /><sentence text="9, 53" /><sentence text="9, 31" /><sentence text="5, and 61" /><sentence text="0 μM, respectively, for uptake mediated by organic anionic transporter polypeptide 1B3 (OATP1B3)" /><sentence text=" Streptomycin and linezolid showed greater inhibition of organic anionic transporter polypeptide 2B1 (OATP2B1)-mediated uptake, with IC50 values of 33"><entity charOffset="1-13" id="DDI-PubMed.26976869.s15.e0" text="Streptomycin" /><entity charOffset="18-27" id="DDI-PubMed.26976869.s15.e1" text="linezolid" /><pair ddi="false" e1="DDI-PubMed.26976869.s15.e0" e2="DDI-PubMed.26976869.s15.e0" /><pair ddi="false" e1="DDI-PubMed.26976869.s15.e0" e2="DDI-PubMed.26976869.s15.e1" /></sentence><sentence text="2 and 35" /><sentence text="6 μM, respectively, along with mild inhibition of other drugs" /><sentence text=" Furthermore, rifabutin, amoxicillin, and rifapentine significantly inhibited OATP1B1-mediated rosuvastatin uptake, with IC50 values of 12"><entity charOffset="14-23" id="DDI-PubMed.26976869.s18.e0" text="rifabutin" /><entity charOffset="25-36" id="DDI-PubMed.26976869.s18.e1" text="amoxicillin" /><entity charOffset="42-53" id="DDI-PubMed.26976869.s18.e2" text="rifapentine" /><entity charOffset="95-107" id="DDI-PubMed.26976869.s18.e3" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.26976869.s18.e0" e2="DDI-PubMed.26976869.s18.e0" /><pair ddi="false" e1="DDI-PubMed.26976869.s18.e0" e2="DDI-PubMed.26976869.s18.e1" /><pair ddi="false" e1="DDI-PubMed.26976869.s18.e0" e2="DDI-PubMed.26976869.s18.e2" /><pair ddi="false" e1="DDI-PubMed.26976869.s18.e0" e2="DDI-PubMed.26976869.s18.e3" /><pair ddi="false" e1="DDI-PubMed.26976869.s18.e1" e2="DDI-PubMed.26976869.s18.e1" /><pair ddi="false" e1="DDI-PubMed.26976869.s18.e1" e2="DDI-PubMed.26976869.s18.e2" /><pair ddi="false" e1="DDI-PubMed.26976869.s18.e1" e2="DDI-PubMed.26976869.s18.e3" /><pair ddi="false" e1="DDI-PubMed.26976869.s18.e2" e2="DDI-PubMed.26976869.s18.e2" /><pair ddi="false" e1="DDI-PubMed.26976869.s18.e2" e2="DDI-PubMed.26976869.s18.e3" /></sentence><sentence text="3, 13" /><sentence text="0, and 11" /><sentence text="0 μM, respectively, which showed a similar profile to estrone-3 sulfate uptake"><entity charOffset="54-71" id="DDI-PubMed.26976869.s21.e0" text="estrone-3 sulfate" /></sentence><sentence text=" The calculated R values ([I]u inlet,max/Ki, where [I]u inlet,max represents the maximum estimated inhibitor concentration inlet to the liver and Ki is the inhibition constant) as the drug-drug interaction (DDI) indexes of PAS, ethambutol, and amoxicillin were 26"><entity charOffset="228-238" id="DDI-PubMed.26976869.s22.e0" text="ethambutol" /><entity charOffset="244-255" id="DDI-PubMed.26976869.s22.e1" text="amoxicillin" /><pair ddi="false" e1="DDI-PubMed.26976869.s22.e0" e2="DDI-PubMed.26976869.s22.e0" /><pair ddi="false" e1="DDI-PubMed.26976869.s22.e0" e2="DDI-PubMed.26976869.s22.e1" /></sentence><sentence text="1, 6" /><sentence text="5, and 4" /><sentence text="3 for OATP1B1 and 52" /><sentence text="0, 8" /><sentence text="0, and 4" /><sentence text="6 for OATP1B3, and those for streptomycin, amikacin, and linezolid were 5"><entity charOffset="29-41" id="DDI-PubMed.26976869.s28.e0" text="streptomycin" /><entity charOffset="43-51" id="DDI-PubMed.26976869.s28.e1" text="amikacin" /><entity charOffset="57-66" id="DDI-PubMed.26976869.s28.e2" text="linezolid" /><pair ddi="false" e1="DDI-PubMed.26976869.s28.e0" e2="DDI-PubMed.26976869.s28.e0" /><pair ddi="false" e1="DDI-PubMed.26976869.s28.e0" e2="DDI-PubMed.26976869.s28.e1" /><pair ddi="false" e1="DDI-PubMed.26976869.s28.e0" e2="DDI-PubMed.26976869.s28.e2" /><pair ddi="false" e1="DDI-PubMed.26976869.s28.e1" e2="DDI-PubMed.26976869.s28.e1" /><pair ddi="false" e1="DDI-PubMed.26976869.s28.e1" e2="DDI-PubMed.26976869.s28.e2" /></sentence><sentence text="0, 4" /><sentence text="2, and 4" /><sentence text="4 for OATP2B1, respectively, suggesting a higher possibility of in vivo DDIs" /><sentence text=" This study is the first comprehensive report to show the novel inhibitory potential of 22 marketed anti-TB drugs on OATP-mediated uptake, providing evidence for future in vivo clinical DDI studies" /><sentence text="" /></document>